This mutation is clinically significant, giving rise to the SQT1 variant of short QT syndrome [49] and exerts only a modest effect (1.5-fold IC50 elevation) on IhERG blocking potency of racemic disopyramide [9, 25]. The gene discussed is KCNH2; the disease is short QT syndrome.